Evidence map›Paper›PMID 40114580›Full record

ArticleJournal of global health2025

Global distribution of prognostically significant pulmonary pressure indicative of pulmonary hypertension.

Geoff A Strange, Bradley A Maron, Katarina Zeder, Yih-Kai Chan, Alexander Chen, David Playford, Marc Humbert, Ana O Mocumbi, Simon Stewart

Abstract read
In one paragraph

Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Geoff A StrangeHeart Research Institute, University of Sydney, Sydney, Australia.
Bradley A MaronDivision of Cardiovascular Medicine, University of Maryland School of Medicine, University of Maryland, Bethesda, Maryland, USA.
Katarina ZederDivision of Cardiovascular Medicine, University of Maryland School of Medicine, University of Maryland, Bethesda, Maryland, USA.
Yih-Kai ChanMary MacKillop Institute for Health Research Australian Catholic University, Melbourne, Australia.
Alexander ChenTorrens University Australia, Adelaide, Australia.
David PlayfordInstitute for Health Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia.
Marc HumbertUniversité Paris-Saclay, Inserm UMR_S 999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
Ana O MocumbiInstituto Nacional de Saúde, Marracuene, Mozambique.
Simon StewartInstitute for Health Research, University of Notre Dame Australia, Fremantle, Western Australia, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There remains a paucity of data to describe how many people worldwide are affected by pulmonary hypertension (PH), an insidious condition associated with adverse vascular remodelling, progressive heart failure, and death without proactive diagnosis and management. Methods: We combined data on the population rate of echocardiographic investigations with tricuspid regurgitant velocity (TRV) levels observed within a clinical cohort of >500 000 people, to conservatively estimate the number of adults with mild (TRV 2.5-2.8 m/s), moderate (TRV 2.9-3.4 m/s) and severe (>3.4 m/s) PH in Australia. We then applied the estimated number of PH cases (age- and sex-specific) to World Bank population estimates for 2021. Results: We conservatively estimate that 16.01 (95% confidence interval (CI) = 15.31-16.71) million men and 15.53 (95% CI = 14.79-16.27) million women, representing 0.616% (95% CI = 0.589-0.643%) and 0.589% (95% CI = 0.561-0.617%) of those aged 20-79 years worldwide, are affected by mild to severe forms of PH. The highest to lowest proportion of cases occur in Southern/Western Europe ( ~ 0.84% men and ~ 0.76% women) and sub-Saharan Africa ( ~ 0.40% both sexes), respectively. In absolute terms, the greatest number of PH cases reside in Eastern ( ~ 9.0 million) and Southern ( ~ 6.5 million) Asia. PH associated with left heart disease is predominant globally, with an estimated 8.7 (0.33%) and 7.5 (0.28%) million male and female cases worldwide. However, in sub-Saharan Africa, those aged <45 years and without left heart disease account for 11.7% of all PH cases compared to <4.0% of cases in Europe/North America. Conclusions: For the first-time, we provide conservative estimates of the global pattern of PH (affecting ~ 31.5 million people). These findings provide a rationale for more definitive burden-of-disease studies focusing on likely regional differences in causality and how PH might be successfully prevented/treated.

Indexed as

Global HealthHypertension, PulmonaryAdultAgedAustraliaEchocardiographyFemaleHumansMaleMiddle AgedPrognosisYoung Adult

Identifiers

PMID40114580
PMCPMC11926580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.